Given that failure in myelination causes impairments in signal conduction in affected nerves, and ultimately loss of motor coordination and balance [3, 36], targeting BubR1 may be of distinct interest towards the development of novel therapies treating myelination-related disorders such as multiple sclerosis, leukodystrophies, and spinal cord injury. Here, BUB1B is linked to multiple sclerosis.